Neurochem Gets Second FDA “Approvable” Letter For Kiacta
FDA suggests that it may require an additional clinical efficacy trial with a p-value of 0.05 or less.
FDA suggests that it may require an additional clinical efficacy trial with a p-value of 0.05 or less.